Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
Int J Mol Sci. 2022 Jan 8;23(2):662. doi: 10.3390/ijms23020662.
Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease worldwide, mirroring the epidemics of obesity and metabolic syndrome. As there are still no licensed medications for treating the disease, there is an ongoing effort to elucidate the pathophysiology and to discover new treatment pathways. An increasing body of evidence has demonstrated a crosstalk between the gut and the liver, which plays a crucial role in the development and progression of liver disease. Among other intestinal factors, gut permeability represents an interesting factor at the interface of the gut-liver axis. In this narrative review, we summarise the evidence from human studies showing the association between increased gut permeability and NAFLD, as well as with type-2 diabetes and obesity. We also discuss the manipulation of the gut permeability as a potential therapeutical target in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）代表着全球范围内日益增多的肝脏疾病病因，与肥胖症和代谢综合征的流行相吻合。由于目前尚无治疗该病的许可药物，因此人们一直在努力阐明其病理生理学，并发现新的治疗途径。越来越多的证据表明，肠道和肝脏之间存在相互作用，这在肝病的发生和发展中起着至关重要的作用。在其他肠道因素中，肠道通透性作为肠-肝轴界面上的一个有趣因素。在本综述中，我们总结了来自人类研究的证据，这些证据表明肠道通透性增加与 NAFLD 以及 2 型糖尿病和肥胖症之间存在关联。我们还讨论了作为 NAFLD 患者潜在治疗靶点的肠道通透性的调控。
